Atosiban vs. ritodrine as a tocolytic in external cephalic version at term: a prospective cohort study.
To compare the success rate of external cephalic version (ECV) at term using ritodrine or atosiban as a tocolytic agent.



Prospective cohort study with a sample of 236 pregnant women with a breech presentation at term, from November 2006 to March 2008. Data have been analyzed from the moment the cephalic version is performed until the time of delivery.



ECV success rate using ritodrine as a tocolytic agent was 56.8% compared to 31.4% with atosiban. Ritodrine increases the version success potential more significantly than atosiban (P<0.05). In both cases, the use of ECV reduced the rate of cesarean sections, although a higher number of versions are required with atosiban [numbers needed to treat (NNT)=9.08] to avoid a cesarean section compared to ritodrine (NNT=3.41).



Ritodrine seems better than atosiban as tocolytic agent for ECVs.
Burgos
Jorge
J
Department of Obstetrics and Gynecology, Cruces University Hospital, Baracaldo, Vizcaya, Spain. jburgoss@sego.es
Eguiguren
Nekane
N
Quintana
Eider
E
Cobos
Patricia
P
Centeno
Maria del Mar
Mdel M
Larrieta
Rosa
R
Fernández-Llebrez
Luis
L
D000328:Adult; D005260:Female; D006801:Humans; D011247:Pregnancy; D011446:Prospective Studies; D012312:Ritodrine / Q000008:administration & dosage*; D015145:Tocolysis; D015149:Tocolytic Agents / Q000008:administration & dosage*; D016896:Treatment Outcome; D014668:Vasotocin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014710:Version, Fetal
D015149:Tocolytic Agents; C047046:atosiban; D012312:Ritodrine; D014668:Vasotocin